Clincosm LogoSign in Get a demo

refractory tumor

Showing 1 - 13 of 13
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor, Adult, Refractory Tumor Trial in Dallas, San Antonio (DCR-STAT3)

Recruiting
  • Solid Tumor, Adult
  • Refractory Tumor
  • Dallas, Texas
  • +1 more
Oct 21, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Radiotherapy, PD-1/PD-L1 inhibitor, Granulocyte-macrophage

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Radiotherapy
  • +4 more
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Sep 14, 2023

Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

Recruiting
  • Advanced Solid Tumor
  • Refractory Tumor
  • Suzhou, China
    The Second Affiliated Hospital of SchoowUniversity
Mar 29, 2023

Refractory Tumor, Solid Tumor Trial in Kaohsiung, Tainan (Dendritic Cell Vaccine, Lenvatinib, Nivolumab)

Not yet recruiting
  • Refractory Tumor
  • Solid Tumor
  • Dendritic Cell Vaccine
  • +2 more
  • Kaohsiung, Taiwan
  • +2 more
Mar 2, 2023

Adult Solid Tumor, Advanced Solid Tumor, Refractory Tumor Trial in Bruxelles, Edegem, Rotterdam (DO-2)

Recruiting
  • Adult Solid Tumor
  • +2 more
  • Bruxelles, Belgium
  • +2 more
Mar 1, 2023

Refractory Cancer, Refractory Tumor, Cancer Pediatric Trial in United States (9-ING-41, Irinotecan, Temozolomide)

Recruiting
  • Refractory Cancer
  • +10 more
  • Aurora, Colorado
  • +7 more
Dec 31, 2022

Solid Tumor, Relapsed Solid Tumor, Refractory Tumor Trial in United States (STI-6643)

Recruiting
  • Solid Tumor
  • +2 more
  • STI-6643
  • San Diego, California
  • +4 more
Jun 30, 2022

Solid Tumor, Refractory Tumor, Relapsed Solid Tumor Trial (STI-3031)

Withdrawn
  • Solid Tumor
  • +2 more
  • STI-3031
  • (no location specified)
Mar 9, 2022

Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)

Recruiting
  • Rare Tumor
  • Refractory Tumor
  • Shanghai, Shanghai, China
    Shanghai Changzheng Hospital
Feb 16, 2022

Squamous Cell Carcinoma of Head and Neck, NSCLC, Colorectal Tumors Trial in Los Angeles (AFM24, SNK01)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • +5 more
  • Los Angeles, California
    USC/Norris Comprehensive Cancer Center
Jan 26, 2022

Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor Trial in United States (Ramucirumab)

Completed
Has Results
  • Pediatric Solid Tumor
  • +3 more
  • Birmingham, Alabama
  • +20 more
Jul 23, 2021

Bone Cyst Aneurysmal, Pathological Fracture, Recurrent Disease Trial (Denosumab (Xgeva))

Completed
  • Bone Cyst Aneurysmal
  • +3 more
  • Denosumab (Xgeva)
  • (no location specified)
Jan 29, 2018

NPC, Refractory Tumor Trial in Singapore (OPB-111077)

Unknown status
  • NPC
  • Refractory Tumor
  • Singapore, Singapore
    National University Hospital, Singapore
Jun 14, 2017